75 results about "Angiogenin" patented technology

Methods of enhancing the bio-availability of coenzyme Q10, and methods of supporting the cardiovascular system to accommodate the increase in cellular energy synthesis as a result of the bio-availability of coenzyme Q10 are described. Compositions which include coenzyme Q10, lactoferrin and / or angiogenin are described for use in the related methods, for multi-functional health applications.

The invention discloses a whitening cosmetic product, a preparation method and application thereof. The whitening cosmetic product comprises the components in percentage by mass: 0.00001to 0.001 percent of recombined human angiogenin, 0.00001 to 0.001 percent of metallothionein, 0.00001 to 0.001 percent of human epidermal growth factor, 0.00001to 0.001 percent of IL-1RA, 0.1 to 0.5 percent of superoxide dismutase, 0.1 to 0.5 percent of low molecular liquaemin, 1 to 5 percent of arbutin, 5 to 25 percent of stabilizer, 0.02 to 0.3 percent of hyaluronic acid, 0.5 to 5 percent of methylpropanediol, 0.5 to 3.5 percent of lactobacillus / mung bean fermentation liquid, 0.5 to 5 percent of dissolved protease, 0.5 to 8 percent of vitamin C sodium phosphate, 0.3 to 0.7 percent of 1,2-hexanediol or 1,2-capryl glycol, 1 percent to 5 percent of oat Beta-glucan, 1 to 5 percent of soy isoflavone and the balance of water. The whitening cosmetic product can be preserved for a long time, has no side effect on skin and is suitable for long term use.

The invention relates to the use of angiogenin, or a fragment or variant thereof, to treat diseases or conditions characterised by neuronal injury or death, or axonal degeneration, especially neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). The invention also describes a plurality of mutations of the human angiogenin gene which are associated with a neurodegenerative disease phenotype, and particularly a ALS phenotype. Also described is a method of assessing whether an individual is afflicted with, or generically predisposed to develop, a disease or condition characterised by neuronal injury or death, or axonal degeneration.

Disclosed herein are methods for diagnosing or treating pregnancy related hypertensive disorders that include the use of a polypeptide or a nucleic acid encoding a polypeptide selected from the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, lanosterol synthase, calcium / calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehyrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by non-covalent immobilization on a naturally occurring substrate, such as a protein, lipid, nucleic acid or nucleotide substrate, are disclosed.

Mutant forms of ribonuclease inhibitor are described which are rendered more resistant to oxidation while retaining affinity for both ribonuclease and angiogenin. The mutant forms have another amino acid, typically an alanine, substituted for one or more of the adjacent cysteine residues in the wild-type sequence to prevent the formation of unwanted disulfide bonds which can disrupt the effectiveness of the molecule.

Methods of enhancing the bio-availability of coenzyme Q10, and methods of supporting the cardiovascular system to accommodate the increase in cellular energy synthesis as a result of the bio-availability of coenzyme Q10 are described. Compositions which include coenzyme Q10, lactoferrin and / or angiogenin are described for use in the related methods, for multi-functional health applications.

Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by covalent immobilization on a naturally occurring substrate, such as a polysaccharide substrate, are disclosed. In particular, the polysaccharide substrate includes galactose-rich polysaccharide.

The invention relates to the use of angiogenin, or a fragment or variant thereof, to treat diseases or conditions characterised by neuronal injury or death, or axonal degeneration, especially neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). The invention also describes a plurality of mutations of the human angiogenin gene which are associated with a neurodegenerative disease phenotype, and particularly a ALS phenotype. Also described is a method of assessing whether an individual is afflicted with, or generically predisposed to develop, a disease or condition characterised by neuronal injury or death, or axonal degeneration.

The preparation process of porous heparinized collagen / chitosan rack with compounded angiogenin includes the following steps: dissolving ox tendon and chitosan separately in acetic acid solution to compound 0.5-5 % concentration solution, mixing chitosan solution in 5-30 % and ox tendon solution, molding and freeze drying to obtain porous collagen / chitosan rack; vacuum treatment, soaking the porous collagen / chitosan rack inside 2-N-morpholynyl ethane sulfonic acid solution of heparin sodium, treating with 1-ethyl-3-3-(dimethylaminopropyl)-carbonized diimine solution and N-hydroxy batanimide solution, washing, re-freezing to dry and to obtain porous heparinized collagen / chitosan rack; and soaking the porous heparinized collagen / chitosan rack inside angiogenin solution to obtain the porous heparinized collagen / chitosan rack with compounded angiogenin. The prepared rack has proper pore size and porosity and is used as the corium substitute in skin tissue engineering.

Disclosed herein are methods for diagnosing or treating pregnancy related hypertensive disorders that include the use of a polypeptide or a nucleic acid encoding a polypeptide selected from the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1- anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, lanosterol synthase, calcium / calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehyrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

The invention concerns a method for production of lactoferrin comprising at least the steps of: a) disposing of raw material that have not been treated at a temperature greater than 500 C, b) submitting this raw material to a treatment in order to obtain a solution of Lactenin (LN) or Milk Basic Protein (MBP), c) submitting this LN or MBP solution to a step of purification on a cation exchange resin equilibrated with an acetate buffer at a pH between 4 and 9 and eluted with different buffer solutions containing different solute concentrations, d) and collecting a fraction containing Lactoferrin having more than 95% of purity, having no polymers and substantially free of LPS, endotoxins and angiogenin. It also concerns the Lactoferrin obtained having more than 95% of purity, substantially free of LPS, endotoxins and angiogenin with an iron saturation level comprised between 9% to 15%.

The invention provides methods for enriching a milk extract for angiogenin, such methods involving separation by size, charge or immunoaffinity. The invention also provides the angiogenin enriched extract produced by the methods and provides them in pharmaceutical and neutraceutical compositions and foods for treating a variety of diseases or disorders that can be treated by angiogenin.

The invention concerns a method for production of lactoferrin comprising at least the steps of: a) disposing of raw material that have not been treated at a temperature greater than 500C, b) submitting this raw material to a treatment in order to obtain a solution of Lactenin (LN) or Milk Basic Protein (MBP), c) submitting this LN or MBP solution to a step of purification on a cation exchange resin equilibrated with an acetate buffer at a pH between 4 and 9 and eluted with different buffer solutions containing different solute concentrations, d) and collecting a fraction containing Lactoferrin having more than 95% of purity, having no polymers and substantially free of LPS, endotoxins and angiogenin. It also concerns the Lactoferrin obtained having more than 95% of purity, substantially free of LPS, endotoxins and angiogenin with an iron saturation level comprised between 9% to 15%.

The invention relates to a preparation method of umbilical cord mesenchymal stem cell liquid for beautifying and maintenance, and belongs to the technical field of medical beautifying. The method comprises the following steps of 1, obtaining umbilical cord stem cells; 2, conducting subculture; 3, preparing the umbilical cord stem cell liquid. According to the technical scheme, umbilical cord stemcells can secrete various cell growth factors to provide a good microenvironment for skin epidermal cells, wherein the cell growth factors include the fibroblastoma growth factor, the fibroblast growth factor, the hepatocyte growth factor, the insulin growth factor, angiogenin and the like; the in-vitro proliferation and migration of human keratinocytes can be activated, skin regeneration and skinwound healing are promoted when the factors enter the skin, the maturity of the skin epidermal cells can be promoted, the skin elasticity is improved, the skin is moisturized, wrinkles are eliminated, pigmentation is prevented, and the liquid has a good beautifying effect.

The invention provides a process for the preparation of an angiogenin-enriched fraction from a milk product, the process comprising contacting the milk product with a cation exchange resin and eluting the angiogenin-enriched fraction from the cation exchange resin with a mobile phase. The invention also provides angiogenin-enriched fractions produced by process and food products, neutraceuticals and pharmaceutical comprising such angiogenin.

The present invention provides a pharmaceutical composition for the prevention or treatment of glaucoma, wherein the pharmaceutical composition includes angiogenin or a fragment thereof as an active ingredient. Angiogenin or a fragment thereof according to the present invention activates aqueous humor outflow due to NO generation increase, Schlemm's canal expansion, and intercellular interval widening, thereby reducing intraocular pressure. Accordingly, angiogenin and a fragment may be useful for the prevention and treatment of glaucoma.

The invention relates to a protein material includes angiogenin and / or angiogenin hydrolysate in an amount of 2 to 15 mg / 100 mg, and lactoperoxidase and / or lactoperoxidase hydrolysate, in the mass ratio to angiogenin and / or angiogenin hydrolysate of 0.3 to 20.

The invention relates to a powdered milk product includes angiogenin and / or angiogenin hydrolysate in an amount of 1.4 to 24 mg / 15 g, and lactoperoxidase and / or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and / or angiogenin hydrolysate of 0.35 to 10.

The invention relates to provide a fermented milk product includes angiogenin and / or angiogenin hydrolysate in an amount of 0.9 mg / 100 g to 150 mg / 100 g, and lactoperoxidase and / or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and / or angiogenin hydrolysate of 0.3 to 23.

The invention relates to a cheese includes angiogenin and / or angiogenin hydrolysate in an amount of 6.5 mg / 100 g to 160 mg / 100 g, and lactoperoxidase and / or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and / or angiogenin hydrolysate of 0.3 to 33.

The invention relates to a drink includes angiogenin and / or angiogenin hydrolysate in an amount of more than 0.8 mg / 100 ml and not more than 150 mg / 100 ml, and lactoperoxidase and / or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and / or angiogenin hydrolysate of 0.3 to 23.

The present invention relates to plant-produced angiogenins, to related plant cells, plant calli, plants, seeds and other plant parts and products derived therefrom and to uses of plant-produced angiogenins. The present invention also relates to expression of angiogenin genes in plants and to related nucleic acids, constructs and methods.

The present invention relates to a method of diagnosis or prognosis of a mammalian wound infection, said method comprising the step of measuring the level of at least on angiogenic factor in a sample of wound fluid. The preferred angiogenic growth factors are angiogenin and vascular endothelial growth factor (VEGF). The present invention also provides devices (e.g. biosensors) for use in such methods, and methods and products for diagnosing and treating infected wounds.

The present invention provides a nucleotide-angiogenin conjugated element (ABE) for inhibiting rRNA synthesis induced by angiogenin. The length of the described oligonucleotide is 10-150 bp, and its C+T content is 80%-100% of all the oligonucleotides, and it contains 5-30 continuous CT repetitive units. The experiments show that the specific combination of ABE and angiogenin can inhibit the synthesis of rRNA, and the animal experiments also show that ABE can inhibit the growth of human tumor on naked mouse.

The present invention provides a skin-whitening product which contains human angiogenin with effective concentration to inhibit the production of melanose of skin, said effective concentration is 0.000001% to 0.1% of total weight. Said product can be used for removing freckle, black spot, aged-mark, melanotic nevus and dermal abnormal change due to melanosis, and / or can be used for eliminating wrinkles, raising skin elasticity and preventing dermal senility.

The invention relates to a cheese includes angiogenin and / or angiogenin hydrolysate in an amount of 6.5 mg / 100 g to 160 mg / 100 g, and cystatin and / or cystatin hydrolysate in the mass ratio to the angiogenin and / or angiogenin hydrolysate of 0.02 to 1.6.

The invention uses biology information to reconstruct Ang crystal structure, and construct the 3D structure, and construct the lacunae mutant that the N end lack 5 amino acid and the C end lack 12 amino acid, the reconstructed Ang mutant would be constructed by gene reconstructing and expression technology. The invention supplies a new method for curing tumor.